We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01682213
Recruitment Status : Active, not recruiting
First Posted : September 10, 2012
Last Update Posted : June 14, 2017
Sponsor:
Collaborators:
National Comprehensive Cancer Network
Novartis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 2018
  Estimated Study Completion Date : September 2018